Opko Launch Brings 4Kscore Prostate Cancer Test to New European Territories | GenomeWeb

NEW YORK (GenomeWeb) – Opko Health said this week that it has launched sales of its 4Kscore prostate cancer risk test in additional European territories.

Opko launched the test through its wholly owned subsidiary, Opko Health Spain in partnership with Barnaclínic, a branch of Hospital Clínic de Barcelona. The release follows the US launch of the test earlier this year and a 2012 European launch covering the UK, Ireland, Sweden, and Denmark.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.